Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 12

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 12
---
 capture might be feasible. 

Acute
infection with many different organisms (e.g. Borrelia, SARS-Cov-2, Epstein Barr virus) trigger “Long Syndromes” in a minority
of cases, characterized by cognitive dysfunction, fatigue and post-exertional malaise.5 For many years, such conditions have
been confusing to the mainstream medical community because there may not be formal diagnostic criteria or an established theory of disease.
This is changing with the advent of Long COVID, and a recent prominent paper outlined the pathophysiological mechanisms for the first
time.6 Although there is not yet supporting evidence in the medical literature, some key opinion leaders in the Lyme community
have postulated, using the veterinary literature as an analog, that life-long infection by sequestering forms of Babesia (e.g.,
B. odocoilei) may be a significant driver of chronic fatigue symptoms.7 If this is true, the addressable market for
antibabesial drugs may be substantially larger than stated above, since the prevalence of chronic fatigue syndrome in the U.S. is at
least 3.3 million cases (excluding Long COVID and PTLDS).8

    ●
    Treatment
    of Acute Babesiosis. There are up to 38,000 cases of potentially treatable acute symptomatic babesiosis (red blood cell infections
    caused by deer tick bites) in the United States each year.9 Approximately 650 of these cases are hospitalizations, a smaller
    fraction of which represents immunosuppressed individuals.10 Symptomatic babesiosis is usually treated with a minimum
    ten day course of atovaquone and azithromycin which is extended to six weeks in the immunosuppressed, who may also experience relapses
    requiring multiple hospitalizations.11 This is much longer than equivalent serious parasitic diseases such as malaria
    where the goal is a three-day regimen. In a recently published case series Tafenoquine in combination with standard of care cured
    80% of immunosuppressed patients with relapsing babesiosis and the investigators stated in a press release that “Tafenoquine
    is going to make a huge difference, I think, in people who are severely immunocompromised.” 12

    1
    See https://www.cdc.gov/lyme/signs-symptoms/chronic-symptoms-and-lyme-disease.html.